Prutis (Nintedanib) Soft Gelatin Capsules: An Antifibrotic Solution for Lung Fibrosis
Prutis, containing Nintedanib, is a soft gelatin capsule designed to manage various forms of lung fibrosis, including Idiopathic Pulmonary Fibrosis (IPF), Interstitial Lung Disease (ILD), and Systemic Sclerosis-associated ILD (SSc-ILD). Classified as an antifibrotic medicine, Nintedanib works by slowing the progression of lung scarring, improving patients’ quality of life.
Uses of Nintedanib:
Nintedanib is primarily prescribed for:
-
IPF treatment – a chronic lung disease causing progressive scarring of lung tissue.
-
ILD management – addressing fibrosis from various interstitial lung disorders.
-
SSc-ILD care – managing lung involvement in systemic sclerosis.
Available in 150 mg and 100 mg soft gelatin capsules, Nintedanib is taken orally under a doctor’s supervision, usually twice daily.
Mechanism of Action:
Nintedanib inhibits multiple tyrosine kinases involved in the fibrotic process, such as VEGFR, FGFR, and PDGFR, reducing fibroblast activation and slowing collagen deposition. By targeting these pathways, it effectively slows lung fibrosis and preserves lung function over time.
Side Effects:
While Nintedanib is generally well-tolerated, some patients may experience:
-
Gastrointestinal issues like diarrhea, nausea, or vomiting
-
Liver enzyme elevation
-
Fatigue or mild headache
-
Appetite loss
Regular monitoring by healthcare professionals is essential to manage side effects and adjust dosage if needed.
Conclusion:
Prutis (Nintedanib) represents a significant advancement in antifibrotic therapy, providing hope for patients with progressive lung fibrosis. Early diagnosis and timely treatment can help manage pulmonary fibrosis symptoms effectively, slowing disease progression and improving quality of life.